Study S000090

A Randomized, Active-comparator Controlled, Parallel-group Study, to Evaluate the Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05140694
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 135
Start: 2023-12-01
Primary completion: 2024-06-30
Lead sponsor: Seoul National University Bundang Hospital
Conditions: Metabolic-associated Fatty Liver Disease; Type 2 Diabetes
Interventions: DRUG:Empagliflozin; DRUG:Dulaglutide; DRUG:Empagliflozin and Dulaglutide
Results posted: FALSE

Registered primary outcomes

Changes of HbA1c level [baseline, week 12, week 24]
Changes of CAP score [baseline, week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.